Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-122 plus obinutuzumab in relapsed/refractory DLBCL and indolent non-Hodgkin lymphoma
NL-OMON56451Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avadomide and obinutuzumab in diffuse large B-cell lymphoma (DLBCL), indolent lymphoma, follicular lymphoma (FL) and 1 more (3 arms), sponsored by Celgene Corporation. Primary endpoints: Safety and tolerability and Non-tolerated dose, maximum tolerated dose, and recommended phase 2 dose. Started Jul 2015; status: completed.
02
Drugs
avadomideobinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)indolent lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NL-OMON56451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56451.